Eli Hurvitz led Teva from the 1976 merger of Teva, Assia and Zori until 2002. The company expanded from its Israeli base through international market entry and acquisitions, including Orphahell in 1977, IVAX in 2006, Barr in 2008 and ratiopharm in 2010.
Hurvitz’s strategy and Teva’s first steps abroad
Hurvitz joined Assia in 1953 and rose through its management before initiating the 1976 consolidation that created Teva Pharmaceutical Industries. His tenure as chief executive lasted until 2002. The Israel Democracy Institute’s biography documents his leadership, while Teva’s company chronology records the company’s international expansion.
Teva’s first overseas acquisition was Dutch firm Orphahell in 1977. Expansion accelerated as the company entered the United States generics market and built positions in Europe. The strategy relied on acquiring established companies and their products, regulatory portfolios and sales networks.
IVAX and Barr widened the business
Teva completed its acquisition of Florida-based IVAX in January 2006. Its announcement said the combined company would operate in more than 60 countries and employ about 26,000 people. The completion release highlighted IVAX products in respiratory medicine, central nervous system treatments and oncology.
In 2008, Teva agreed to acquire Barr Pharmaceuticals for $7.46 billion plus assumed net debt of about $1.5 billion. Barr brought a large U.S. generics business and its European subsidiary PLIVA. Teva’s deal announcement set out the proposed terms and geographic reach.
ratiopharm strengthened Teva in Europe
In 2010, Teva completed its purchase of German generic drug maker ratiopharm. The acquisition added a substantial European business and reinforced Teva’s position in generic medicines. Together, these transactions show how a company formed through an Israeli merger developed into an international manufacturer and supplier. The origin story is covered in Teva’s early history; its active ingredient operations are explained in the API business guide.